-
2 days ago | 
brainandlife.org | Fran Kritz
Ethan Henderson, 55, went from taking no drugs to taking seven every day since being diagnosed with Parkinson's disease six years ago. Five of the medications treat his movement symptoms, and two address gastrointestinal problems.
-
3 days ago | 
verywellhealth.com | Fran Kritz |Jennifer Klump
Nearly 20 years ago, Japanese researchers developed “interval walking training,” a simple routine that alternates between slow and fast walking. Now known as “Japanese walking,” the practice has been shown to improve aerobic capacity (VO2max), lower blood pressure, and help regulate blood sugar.
-
1 week ago | 
verywellhealth.com | Fran Kritz |Jennifer Klump
There's one key ingredient that keeps ice cream from melting and peanut butter from separating: emulsifiers. They're used in thousands of food products, but emerging research suggests these common additives may be linked to health risks. Studies have linked emulsifiers to a higher risk of heart disease, type 2 diabetes, and cancer. Synthetic emulsifiers may also contribute to inflammatory bowel diseases (IBD) by disrupting the gut microbiome.
-
1 week ago | 
verywellhealth.com | Fran Kritz |Jennifer Klump
Some people using GLP-1 drugs say they have a persistent bad taste in their mouth, an effect some have dubbed "Ozempic Tongue." A lingering bitter, sour, or metallic taste isn't unique to GLP-1 drugs. For instance, Paxlovid, an antiviral used to treat COVID-19, may also cause a metallic taste in the mouth. During clinical trials for Ozempic, about 0.4% of people who used the drug reported developing dysgeusia, a disorder that alters someone's sense of taste.
-
2 weeks ago | 
verywellhealth.com | Fran Kritz
Considering a healthy snack between meals? A handful of pecans may be a smart choice. A recent study found that eating pecans improved both diet quality and cholesterol levels. The study, published in American Journal of Clinical Nutrition, included 138 adults between ages 25 and 70. The participants had or were at risk for metabolic syndrome—a group of conditions that raise the risk of heart disease, stroke, and type 2 diabetes.
-
3 weeks ago | 
idse.net | Fran Kritz
By Fran KritzThe FDA and CDC recently issued a joint advisory statement recommending a pause in the use of the chikungunya vaccine, live (Ixchiq, Valneva SE), in people 60 years of age and older, while they investigate reports of serious adverse events (AEs). Ixchiq, approved by the FDA in November 2023, is the first of two vaccines recently approved by the FDA to prevent chikungunya.
-
3 weeks ago | 
verywellhealth.com | Fran Kritz |Jennifer Klump
After years of debate, the International Diabetes Federation (IDF) has finally recognized type 5 diabetes as an official diagnosis. Unlike other forms of the condition, type 5 diabetes is linked to childhood malnutrition and affects millions of teens and young adults, mostly in Asia and Africa.
-
1 month ago | 
verywellhealth.com | Fran Kritz |Jennifer Klump
Some food and beverage manufacturers like PepsiCo said they plan to stop using synthetic food colorings after the FDA announced that eight petroleum-based food dyes will be phased out by the end of 2026. According to the FDA, the agency will soon revoke the authorization of Citrus Red No. 2 and Orange B, which the food industry says are rarely used.
-
1 month ago | 
specialtypharmacycontinuum.com | Fran Kritz
By Fran Kritz On April 15, President Trump issued an executive order aimed at lowering prescription drug prices that requires the FDA commissioner to issue a report within 180 days “providing administrative and legislative recommendations to accelerate approval of generics, biosimilars, combination products, and second-in-class brand name medications.” In a fact sheet the White House summarized efforts to increase the availability of generics and biosimilars through measures including:...
-
1 month ago | 
pharmacypracticenews.com | Fran Kritz
Originally published by our sister publication Specialty Pharmacy Continuum By Fran Kritz On April 15, President Trump issued an executive order aimed at lowering prescription drug prices that requires the FDA commissioner to issue a report within 180 days “providing administrative and legislative recommendations to accelerate approval of generics, biosimilars, combination products, and second-in-class brand name medications.” In a fact sheet the White House summarized efforts to increase the...
